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Abstract 
Background: Over 1 billion people suffer from chronic respiratory diseases such as asthma, COPD, rhinitis and 
rhinosinusitis. They cause an enormous burden and are considered as major non‑communicable diseases. Many 
patients are still uncontrolled and the cost of inaction is unacceptable. A meeting was held in Vilnius, Lithuania (March 
23, 2018) under the patronage of the Ministry of Health and several scientific societies to propose multisectoral care 
pathways embedding guided self‑management, mHealth and air pollution in selected chronic respiratory diseases 
(rhinitis, chronic rhinosinusitis, asthma and COPD). The meeting resulted in the Vilnius Declaration that was developed 
by the participants of the EU Summit on chronic respiratory diseases under the leadership of Euforea.
Conclusion: The Vilnius Declaration represents an important step for the fight against air pollution in chronic respira‑
tory diseases globally and has a clear strategic relevance with regard to the EU Health Strategy as it will bring added 
value to the existing public health knowledge.
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Background: chronic respiratory diseases are 
major chronic diseases across the life cycle
Over 1 billion people suffer from chronic respiratory 
diseases such as asthma, COPD, rhinitis and rhinosi-
nusitis. Chronic respiratory diseases are major chronic 
diseases [1]. Asthma and allergic diseases occur along the 
life cycle from early childhood, affecting 30 million chil-
dren and adults under 45 years of age in Europe. COPD 
has an estimated annual death rate of over 4 million 
people globally. The annual costs due to asthma (direct 
costs, indirect costs and loss of productivity) in the EU 
are estimated at 72 b€ and those due to COPD at 142 b€ 
[2]. Work productivity loss due to rhinitis is estimated at 
30–50 b€ [3] and the disease has a major impact on sleep 
and anxiety [4]. Children with early onset asthma, active 
smoking, exposure to tobacco smoke and poverty are 
all risk factors of fixed airflow obstruction in adulthood 
[5–7].
The Polish Presidency of the EU Council (3051st Coun-
cil Conclusions) made the prevention, early diagnosis 
and treatment of asthma and allergic diseases a priority 
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to reduce health inequalities [8, 9]. The 3206th Cyprus 
Council Conclusions [10] recommended that the diagno-
sis and treatment of chronic diseases should be initiated 
as early as possible to improve active and healthy age-
ing (AHA). Several debates at the European Parliament 
recommended an early diagnosis and management of 
chronic respiratory diseases in children in order to pro-
mote AHA (Cyprus Presidency of the EU Council, 2012) 
[11], predictive medicine [12] and self-management 
strategies using mobile technology [13].
The Vilnius EU Summit on the prevention and manage-
ment of chronic respiratory diseases (Vilnius, Lithuania, 
23 March, 2018) followed these recommendations and 
attempted to provide a road map to prevent and control 
chronic respiratory diseases using integrated care path-
ways and the recent advances in mobile technology with 
a focus on air pollution.
Protective and risk factors
Chronic respiratory diseases and other chronic diseases 
often share risk factors (e.g. tobacco, including e-ciga-
rettes, allergen exposure, nutrition, indoor and outdoor 
air pollution and sedentary lifestyle) [1, 14, 15], all lead-
ing to sustained local and systemic inflammation [16, 17] 
as well as ageing. Tobacco smoking is the best identified 
risk factor for many chronic diseases including chronic 
respiratory diseases. Allergens are of importance in rhi-
nitis and asthma. Indoor and outdoor air pollution is 
another important risk factor for chronic respiratory dis-
eases of increasing importance [18–21]. Ecosystems are 
impacted by air pollution, particularly sulphur and nitro-
gen emissions, and by ground-level ozone: these factors 
affect their ability to function and grow and have adverse 
effects on flora and fauna as well as on allergic diseases 
[22]. Moreover, these risk factors can interact to worsen 
chronic respiratory diseases and induce exacerbations 
[23].
Pre-natal and early-life events have a major impact on 
the development of chronic diseases in adults [24, 25] 
and older people. A better understanding of these links 
will enable the implementation of effective novel preven-
tion strategies to promote AHA. The developmental ori-
gin of ageing is on the EU political agenda [9, 10, 26, 27].
Chronic disease prevention and control could be con-
sidered sequentially before the disease has been identified 
(i) to prevent its onset (health promotion and primary 
prevention), and (ii) after its onset, to better control and 
prevent its short- and long-term consequences (second-
ary and tertiary prevention and control). It should also 
be noted that early impairment of lung function is a 
marker of early all-cause systemic morbidity and mortal-
ity [23–25].
Health promotion and prevention should start at con-
ception and continue steadily across the life cycle for 
healthy lungs and active and healthy ageing. They have 
been laid down from a political perspective to contribute 
to the goals of the Europe 2020 strategy of healthy and 
active ageing [28], the Sustainable Development Goals 
for 2030 (SDG) and the WHO strategy on chronic dis-
eases. The strategy was also promoted by the Polish EU 
priority [8, 9]. Multi-sectoral prevention, including pol-
icy change, regulation, and market intervention, is of the 
highest priority.
There is a need to find novel health promotion strate-
gies in chronic respiratory diseases and to promote value 
creation in order to promote AHA. Particular attention 
is required for tobacco smoke prevention and for air pol-
lution mitigation strategies. It should be noted that there 
is ample evidence of the effectiveness of legislation to 
restrict smoking and reduce pollution, and that Govern-
ments should therefore be pushed to implement the best 
environmental policy.
Chronic respiratory diseases will be seriously 
impacted by climate change
Climate change is considered as a major threat for 
chronic respiratory diseases [29, 30]. Heat waves sig-
nificantly increase morbidity and mortality in patients 
with  chronic  lung  disease [31]. Climate change, medi-
ated by greenhouse gases, causes adverse health effects to 
vulnerable chronic respiratory diseases patients includ-
ing the elderly, children, and those in a distressed socio-
economic state [32]. Reducing greenhouse gas emission 
and improving air quality represent two global challenges 
[33].
Poor adherence to medication: a major factor 
in chronic respiratory disease‑related burden 
and death
Public health measures play an essential role in improv-
ing outcomes, but, for conditions where effective medi-
cations are available, such as for non-severe asthma, 
patients are supported in taking their medication effec-
tively. One important global cause of low adherence is 
that medications are not accessible or affordable [14], and 
this issue must be addressed across Europe, especially in 
middle-income countries. If medications are accessible, 
adherence is relatively high. This is a known important 
factor in asthma deaths [15]. Unfortunately, the educa-
tion programmes that have been proposed over the past 
decades have not increased adherence. Innovative effec-
tive educational programmes using mobile technology 
and guided self-management appear to be crucial for the 
empowerment of patients and will increase and support 
their adherence to medications. However, evidence-based 
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real-life studies should be proposed to confirm the 
importance of mHealth and lead to change management 
We need to develop evidence-based strategies to change 
the management of CRDs [34]. School-based interven-
tions are also of great importance. Ensuring that practical 
support strategies are in place also represents an essential 
strategy for improving outcomes. On-demand strategies 
may be of great interest for the improvement of  adher-
ence [35, 36].
Prevention and treatment strategies at national 
or regional levels
Effective strategies are needed to reduce chronic res-
piratory disease burden. National programmes (Finnish, 
Czech, Portuguese Asthma or COPD Programmes) or 
national partnerships against chronic respiratory diseases 
(Italy, Netherlands, Lithuania, France, Romania, Belgium 
and Spain) can be cost-effective [37]. However, they are 
insufficiently implemented in many other EU countries, 
in particular in RIS countries [EIT Regional Innovation 
Scheme (EIT RIS)].
Integrated care pathways (ICPs) exist in some coun-
tries, such as the UK for COPD (QS10) (NICE) [38], 
France (HAS) and the Netherlands [39], but national 
ICPs for asthma or asthma and rhinitis comorbidity do 
not exist. Quality standards for asthma (QS25) have been 
published by NICE [40]. These are specific, concise state-
ments that act as markers of high-quality and cost-effec-
tive patient care. Moreover, some initiatives are aimed at 
also incentivising good practice and improving imple-
mentation (i.e. remuneration based on performance indi-
cators). In the UK, the Quality and Outcomes Framework 
(QOF) has 4 asthma-specific performance indicators 
which are explicitly linked to the subsequent remunera-
tion of providers [41].
The Finnish Asthma 1994–2004 [42] and Allergy Pro-
grammes [43, 44] pioneered the field and have been 
found to be effective [45], demonstrating why public 
health problems need public health solutions. The pro-
grammes have been based on scientific innovations 
turned into practical actions. This has been possible in 
a country where the educational level of citizens is rela-
tively high and where health care is efficiently organ-
ized and mainly funded by public money. Integration of 
the work of primary and secondary care physicians and 
nurses, pharmacists and caregivers has been the key for 
a better flow of information, education and patient care, 
while patient education and public awareness improved 
at the same time by organisations representing patients. 
However, the asthma programme has been successfully 
deployed in Europe [46] and developing countries [1, 37, 
47]. The allergy programme has been deployed in Nor-
way [48]. In asthma, improved detection of disease and 
recognizing asthma as an inflammatory disorder from 
the outset has led to early and effective management [49]. 
In the 2016 Pharmacy Barometer Survey, not more than 
2.5% of Finnish asthma patients reported severe symp-
toms. In allergy, the turning avoidance into tolerance 
strategy, focusing on severe forms of disease and empha-
sizing health rather than mild problems, has encour-
aged a more rationale use of healthcare resources [3]. A 
nationwide cost analysis was also performed (Fig. 1) [50].
The Finish COPD programme has also been a success, 
the prevalence of smoking was reduced in both men and 
Fig. 1 In 2013, direct and indirect asthma and allergy costs were €1.3–1.6 billion in Finland (population 5.5 million). From [50]
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women, there was improved quality of diagnosis and 
reduction in hospitalizations (Fig. 2) [51].
The Finnish experience calls all European communi-
ties to take systematic and coordinated action to improve 
public health by lessening disability and costs caused by 
asthma and allergy. Inadequate care of these conditions 
seems to be a global problem delaying patient manage-
ment and causing poor outcome [64]. Although many 
actions have already been taken in Europe [65], Lithuania 
and Baltic countries can speed up implementation and 
make it relevant to healthcare and society as a whole.
Multisectoral care pathways embedding guided 
self‑management, mHealth and air pollution 
in chronic respiratory diseases
ICPs are structured multidisciplinary care plans which 
detail essential steps in the care of patients [52]. They 
promote the translation of guidelines into local proto-
cols and their subsequent application to clinical practice 
[53]. They empower patients and their carers (health and 
social). ICPs differ from practice guidelines as they are 
utilised by a multidisciplinary team and have a focus on 
the quality and coordination of care. Multisectoral care 
pathways for multimorbid chronic respiratory diseases 
are needed [54] and should incorporate self-management 
and aerobiology to allow precision medicine with endo-
type-driven treatment [55].
A large number of chronic respiratory disease patients 
do not consult physicians because they think their 
symptoms are ‘normal’ and/or trivial. However, chronic 
respiratory diseases including rhinitis and asthma nega-
tively impact social life, school and work productiv-
ity [56]. There is a clear role for the pharmacist for AR 
management in practice, through a guided change man-
agement process.
An example of an ICP has been proposed for allergic 
rhinitis (AR). Many rhinitis patients use over-the-counter 
(OTC) drugs [57] and only a fraction have had a medi-
cal consultation. The vast majority of patients who visit 
GPs or specialists have moderate/severe rhinitis [58–62]. 
GRADE-based guidelines are available for AR and their 
recommendations are similar [63–65]. However, they are 
based on the assumption that patients regularly use their 
treatment and are not tested with real-life data. Unfor-
tunately, adherence to treatment is very low and real-life 
studies do not necessarily accord with all recommenda-
tions [66]. New-generation guidelines embedding real life 
data are needed.
Thus, ICPs should consider a multi-disciplinary 
approach as proposed by AIRWAYS ICPs (Fig. 3), using 
self-medication, shared decision making (SDM) and 
new-generation guidelines including messaging for 
increased adherence and information on aerobiology and 
air pollution.
Self‑care and shared decision making
Self-care is any necessary human regulatory function 
that is under  individual  control, deliberate and self-ini-
tiated. Chronic respiratory diseases require a long-term 
approach with emphasis on patient empowerment and 
appropriate support services stressing the importance 
of health literacy. In self-care, chronic disease patients 
make many day-to-day decisions. Self-management edu-
cation complements traditional patient education. Self-
care is learned, purposeful and continuous, otherwise it 
is dependent only on individuals’ specific circumstances, 
resources, beliefs, etc. Some important targets of self-
care include the prevention of asthma and COPD exac-
erbations [67–69] but also the improvement of control of 
asthma, rhinitis or chronic rhinosinusitis [13, 70].
In shared decision making, both the patient and the 
health care professional contribute to the medical deci-
sion-making process, placing the patient at the centre of 
the decision [71]. For children, caregivers should contrib-
ute to the decision. Physicians explain treatments and 
alternatives to patients who can then choose the treat-
ment option that best aligns with personal beliefs and 
goals and consider the benefits and risks [72]. In contrast 
to shared decision making, the traditional medical care 
system places physicians in a position of authority, with 
patients playing a passive role in care [73].
mHealth including messaging
mHealth has evolved from eHealth, the use of informa-
tion and communication technology (ICT) for health ser-
vices and information transfer. According to the World 
Fig. 2 Hospital admissions were reduced in Finland after initiation of 
the 10‑year COPD programme (from Kinnula et al. [51])
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Health Organization (WHO) [74], mHealth “has the 
potential to transform the face of health service deliv-
ery across the globe. A powerful combination of fac-
tors is driving this change. These include rapid advances 
in mobile technologies and applications, a rise in new 
opportunities for the integration of mobile health into 
existing mHealth services, and the continued growth 
in coverage of mobile cellular networks.” The potential 
applications and benefits of mHealth are extensive and 
expanding [75]. mHealth may be of great value in self-
care and shared decision making.
The potential for mHealth in chronic respiratory dis-
eases is enormous [76] but implementing ICT innova-
tions may also have adverse consequences. It is therefore 
important to test applicability in each individual situation 
[77]. Apps may be used to better understand and improve 
adherence, in particular using messaging, as well as to 
enable shared decision making and improve self-manage-
ment of chronic diseases [78]. Patients, who are the final 
users of these apps, must be included not only in the test-
ing phase, but also in the design and creation [79].
The Vilnius Declaration (VD)
The VD is an essential step for the fight against air 
pollution in chronic respiratory disease globally
A first meeting on air pollution in chronic respiratory 
diseases and mHealth was held during the 11th GARD 
meeting in Brussels (November 10, 2017). It paved the 
way for the VD.
• POLLAR (Impact of Air POLLution on Asthma 
and Rhinitis) [80] is an EIT Health project that will 
propose strategies to predict and prevent air pollu-
tion peaks and chronic respiratory disease morbid-
ity using mobile technology (Paris, January 2018).
• The Vilnius EU Summit (March 2018) prepared the 
VD and proposed a meeting at the UN with the fol-
lowing objectives: (i) to tackle the future risk of air 
pollution and climate change in chronic respiratory 
diseases across the life cycle, (ii) to propose practi-
cal primary and secondary prevention strategies to 
meet this unprecedented public health challenge 
and (iii) to combat inequities.
• The first ever WHO conference on air pollution 
and health was held in Geneva on October 30th–
November 1st 2018, a clear sign that the problem is 
growing and that solutions are needed.
• The 12th GARD meeting in Helsinki (August 2018) 
refined the VD for the UN High-Level Conference.
• An ARIA-Masterclass (with Euforea) was  the first 
teaching session on the subject and focussed on 
ICPs, self-management and shared decision making 
(Brussels, September 12 2018).
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Fig. 3 Integrated care pathways for rhinitis and asthma multimorbidity embedding aerobiology
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• A meeting (HLC) was organized at the UN Assem-
bly (September 27, 2018), the results of which led to 
an action plan for implementing recommendations.
• A consensus meeting was organized (POLLAR, Paris, 
December 2018) to improve care pathway design in 
order to enhance patient participation, health literacy 
and self-care through technology-assisted ‘patient acti-
vation’ using rhinitis and asthma multimorbidity as a 
model of non-communicable disease. Pharmacy guide-
lines were included in this meeting.
• With the results of POLLAR, a consensus meeting 
was  organized (POLLAR, Paris, December 2019) to 
embed aerobiology and air pollution in ICPs.
The VD
The Vilnius Declaration was developed by the partici-
pants of the EU Summit on chronic respiratory diseases 
(Vilnius, March 23, 2018) under the leadership of Euforea 
(“Appendix”).
The expected impact of the VD
The VD has a clear strategic relevance with regard to the 
EU Health Strategy as it will bring added value to the exist-
ing public health knowledge:
• To propose a common framework for integrated care 
pathways in chronic respiratory diseases (and their co-
morbidities) for the entire EU which can be expanded 
to Eastern European and other regions and which will 
allow comparability and trans-national initiatives;
• To help risk stratification in chronic respiratory disease 
patients with a common strategy;
• To develop cost-effective policies, in particular 
strengthening those on smoking, including e-ciga-
rettes, and environmental exposure;
• To propose a common simulation tool for the entire 
EU to assist physicians in the segmentation of patients 
and choice of pathways;
• To develop the interoperability of mHealth systems in 
Europe, including transborder interoperability in East-
ern European regions (border between EU member 
states and associate EU countries);
• To have a significant impact on the health of citizens in 
the short term (reduction of morbidity, improvement 
of education in children and of work in adults) and in 
the long term (healthy ageing).
Conclusions
The Vilnius Declaration represents an important step 
for the fight against air pollution in chronic respiratory 
diseases globally and has a clear strategic relevance with 
regard to the EU Health Strategy as it will bring added 
value to the existing public health knowledge.
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Appendix: the Vilnius Declaration
Introduction
1. The European Forum for Research and Education in 
Allergy and Airway Diseases (Euforea) has developed 
the Vilnius Declaration as a statement to improve the 
guided self-management of chronic respiratory dis-
eases using mHealth and giving special consideration 
to the impact of air pollution and climate change.
2. The Declaration was elaborated and approved dur-
ing the EU Summit on chronic respiratory diseases in 
Vilnius, Lithuania, on 23 March 2018, and addressed 
to health care personnel, policy makers and, most 
importantly, to patients suffering from chronic res-
piratory diseases.
3. Over 1 billion people suffer from chronic respiratory 
diseases such as asthma, Chronic Obstructive Pul-
monary Disease (COPD), rhinitis and rhinosinusitis. 
Chronic respiratory diseases are major chronic dis-
eases.
4. It is the duty of the medical community and health 
care systems to provide patients with tools to assist 
them with the most appropriate treatment and self-
management of their condition.
Chronic respiratory diseases are major chronic diseases 
across the life cycle and are affected by environmental risk 
factors
5. Chronic respiratory diseases and other chronic dis-
eases often share environmental risk factors (e.g. 
tobacco use, including e-cigarettes, nutrition, indoor 
and outdoor air pollution and sedentary lifestyle), 
leading to sustained local and systemic inflammation 
as well as impaired ageing.
6. Asthma and allergic diseases occur along the life 
cycle from early childhood, affecting 30 million 
children and adults under 45 years of age in Europe 
and more than 600 million people globally. COPD is 
responsible for an estimated 3 million deaths globally.
7. Pre-natal and early-life events have a major impact 
on the development of chronic diseases in adults 
and older people. Early impairment of lung function 
is a marker of early all-cause systemic morbidity and 
mortality.
8. Smoking is the most important risk factor for chronic 
respiratory diseases. Indoor and outdoor air pollu-
tion are other important risk factors of increasing 
importance. Allergens are of importance in rhinitis 
and asthma. Moreover, these risk factors can interact 
to worsen chronic respiratory diseases and induce 
exacerbations.
Prevention, control and self‑management of chronic 
respiratory diseases
 9. Chronic disease prevention and control could be 
considered sequentially before the disease has been 
identified (i) to prevent its onset (health promotion 
and primary prevention), and (ii) after its onset, to 
better control and prevent its short- and long-term 
consequences (secondary and tertiary prevention 
and control).
 10. Tobacco smoking is the best identified risk factor 
for many chronic diseases including chronic res-
piratory diseases.
 11. Health promotion and prevention should start at 
conception and be steadily continued across the life 
cycle for healthy lungs and active and healthy age-
ing.
 12. A large number of chronic respiratory disease 
patients do not consult physicians because they 
think their symptoms are trivial. However, chronic 
respiratory diseases, including rhinitis and asthma, 
negatively impact social life, school and work pro-
ductivity.
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 13. Many rhinitis patients use over-the-counter (OTC) 
drugs and only a fraction have had a medical con-
sultation. The vast majority of patients who visit 
general practitioners or specialists have moderate/
severe rhinitis.
 14. Thus, Integrated Care Pathways should consider a 
multi-disciplinary approach including physicians, 
pharmacists and other health care personnel as 
proposed by AIRWAYS ICPs. Self-medication and 
shared decision making should be used as well as 
new-generation guidelines including messaging for 
increased adherence and information on aerobiol-
ogy and air pollution.
 15. Chronic respiratory diseases require a long-term 
approach with emphasis on patient empowerment 
and appropriate support services stressing the 
importance of health literacy.
 16. Self-care  is any necessary human regulatory func-
tion which is under  individual  control, deliberate 
and self-initiated.
 17. In shared decision making, both the patient and the 
physician contribute to the medical decision-mak-
ing process, placing the patient at the centre of the 
decision. Physicians explain treatments and alter-
natives to patients who can then choose the treat-
ment option that best aligns with personal beliefs 
and goals and consider the benefits and risks.
 18. The potential for mHealth in chronic respiratory 
diseases is enormous but implementing Informa-
tion and Communication Technology (ICT) inno-
vations may also have adverse consequences. It is 
therefore important to test applicability in each 
individual situation.
 19. Mobile Applications (Apps) may be used to better 
understand and improve adherence, in particular 
using messaging.
Health system strengthening and Sustainable 
Development Goals (SDG)
The Vilnius Declaration aims to contribute to the follow-
ing actions:
 20. To propose a common framework for integrated 
care pathways in chronic respiratory diseases 
(and their co-morbidities) for the entire EU which 
can be expanded to Eastern European and other 
regions and which will allow comparability and 
trans-national initiatives.
 21. To extend the Finnish experience of population 
management models of long-term state chronic 
respiratory disease control programmes, especially 
in low to middle income countries.
 22. To help risk stratification in chronic respiratory 
disease patients with a common strategy.
 23. To develop cost-effective policies, in particular 
strengthening those on the reduction of smoking, 
including e-cigarettes, and environmental expo-
sure.
 24. To propose a common simulation tool for the 
entire EU to assist physicians in the segmentation 
of patients and choice of pathways.
 25. To develop interoperability of mHealth systems 
in Europe, including transborder interoperability 
in Eastern European regions (border between EU 
member states and associate EU countries).
 26. To have a significant implication on the health of 
citizens in the short term (reduction of morbidity, 
improvement of education in children and of work 
in adults) and in the long term (healthy ageing).
 27. To achieve the goals of the Europe 2020 strategy of 
healthy and active ageing and of the UN Sustain-
able Development Goals to be reached in 2030.
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